← Back
Data updated: Jul 17, 2026
UT SW MEDCTR
Pharma Pharmaceuticals
UT SW MEDCTR is a pharmaceutical company with 1 FDA-approved products.
1988
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Upcoming FDA Decisions
Full Calendar → Jul 23, 2026 — Rivoceranib + camrelizumab
5d Jul 23, 2026 — Rivoceranib + camrelizumab
Aug 10, 2026 — Oveporexton (TAK-861)
UT SW MEDCTR's Key Drugs
UT SW MEDCTR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
UT SW MEDCTR's Recent FDA Approvals
New NDA/BLA approvals for UT SW MEDCTR over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
UT SW MEDCTR's Therapeutic Areas
Disease areas where UT SW MEDCTR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
UT SW MEDCTR Pipeline Snapshot
Active clinical trials for UT SW MEDCTR across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1988-10-13
- Latest
- 1988-10-13
- Applications
- 1